Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...
(MENAFN- 3BL) January 22, 2026 /3BL/ - Medtronic, a global leader in healthcare technology, announced verification study results for its investigational NellcorTM pulse oximetry with Nell-EQTM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results